Femasys (NASDAQ:FEMY) Stock Gets Downgrade from Wall Street Zen

Femasys (NASDAQ:FEMY) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

Other equities research analysts have also issued reports about the company. Weiss Ratings lowered Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Maxim Group cut their price objective on shares of Femasys to $10.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, Lake Street Capital reduced their target price on shares of Femasys to $10.00 and set a “buy” rating for the company in a research note on Tuesday, August 18th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.00.

Femasys Price Performance

FEMY stock opened at $1.42 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.55 and a current ratio of 2.14. The business has a 50-day simple moving average of $2.10 and a two-hundred day simple moving average of $5.84. The company has a market capitalization of $11.90 million, a P/E ratio of -0.40 and a beta of -2.13. Femasys has a 52-week low of $1.25 and a 52-week high of $22.20.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings data on Friday, August 14th. The company reported ($1.33) EPS for the quarter, missing the consensus estimate of ($1.31) by ($0.02). Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%. The company had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.73 million.

About Femasys

Femasys Inc is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures.

Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.